Insys Therapeutics Inc (NASDAQ:INSY) Reports Availability of SYNDROS

Insys Therapeutics Inc (NASDAQ:INSY) reported that SYNDROS™ has been made available for health care executives to prescribe. It is stocked with most of the key wholesalers for retail pharmacy ordering or via the company’s Specialty Pharmacy Network.

The details

SYNDROS can be defined as a liquid formulation of the pharma CBD dronabinol. It is indicated for application in treating anorexia linked with weight loss in people with Acquired Immune Deficiency Syndrome and vomiting and nausea linked with chemotherapy in people with cancer who have failed to respond sufficiently to conventional antiemetic therapies. Saeed Motahari, the CEO and President of Insys, reported that the release of SYNDROS showcases a major milestone for them.

SYNDROS is the second offering entirely advanced and commercialized by Insys Therapeutics. They are thrilled to make SYNDROS accessible to those patients in need and expect to bringing additional unique therapeutic solutions to more patients in the imminent future.

Stephen Sherman, the SVP of Regulatory Affairs with Insys, reported that SYNDROS is the FDA-permitted liquid dronabinol. It showcases a viable option for the delivery of dronabinol and will meet a considerable unmet need for cancer patients undertaking chemotherapy who fail conventional antiemetics and AIDS patients who witness weight loss.

There are currently more than 15 million people diagnosed with cancer in the U.S.  Affecting around 80% of people undergoing chemotherapy, CINV is one of chemotherapy’s most devastating side effects and often attributed as a major reason behind premature discontinuation of cancer treatment. Irrespective of the availability of numerous antiemetics, CINV continues to be a major concern for the cancer patient.

SYNDROS™ may cause cognitive and psychiatric effects and impair physical and/or mental abilities. People with cardiac disorders may witness syncope, tachycardia, hypotension or hypertension. Products should be discontinued containing metronidazole or disulfiram at least 14 days before and should not be administer one week after treatment with SYNDROS™.